Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAMOND: Dato-DXd +/- Durvalumab in PDL1-negative Metastatic TNBC
NCT06954480Phase 2Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Oct 2025
- Primary completion
- Feb 2028
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of datopotamab deruxtecan, durvalumab in triple-negative breast cancer (TNBC), sponsored by Queen Mary University of London. Started Oct 2025; status: recruiting.
02
Drugs
datopotamab deruxtecandurvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06954480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06954480.